Search
Jazz Pharmaceuticals PLC
JAZZAdd to Watchlist
223.000USD
-6.850-2.98%
Close 06/24, 16:00（ET）Quotes delayed by 15 min
13.70BMarket Cap
540.82P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-2.98%
5 Days
-1.73%
1 Month
-7.02%
6 Months
+30.56%
Year to Date
+31.18%
1 Year
+106.27%
Key Figures
229.760Open
234.079High
34.00Volume
540.82P/E TTM
7.89P/E Dynamic
--Dividend TTM
0.00%Turnover Ratio
229.850Prev. Close
228.295Low
6.02KTurnover
24.46P/E Static
3.17P/B
0.00%Div Yield TTM
0.23%ROA
243.32052wk High
-0.00Volume Ratio
560.12MNet Profit
61.44MShares
0.4123EPS TTM
0.32Beta
0.63%ROE
105.00052wk Low
2.52%Amplitude
71.34%Gross Margin
13.70BMarket Cap
-1.82Reward/Risk
1.75%Risk Rate
TradingKey Stock Score of Jazz Pharmaceuticals PLC
Currency: USD Updated: 2026-06-24Key Insights
Jazz Pharmaceuticals PLC's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 23 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 258.27.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Jazz Pharmaceuticals PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Jazz Pharmaceuticals PLC Highlights
StrengthsRisks
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Overvalued
The company’s latest PE is 557.43, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 70.31M shares, decreasing 1.06% quarter-over-quarter.
Held by Tweedy Browne
Star Investor Tweedy Browne holds 47.90K shares of this stock.
Analyst Rating
Based on
19
analysts
Buy
Current Rating
258.275
Target Price
+14.96%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Jazz Pharmaceuticals PLC News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Jazz Pharmaceuticals PLC Info
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Ticker SymbolJAZZ
CompanyJazz Pharmaceuticals PLC
CEOGala (Renee D)
Websitehttps://www.jazzpharma.com/
Related Instruments
-0.37%
0.00%
0.00%
-0.75%
0.00%
+0.06%
0.00%
+0.78%
0.00%
+0.25%
0.00%
0.00%
+0.92%
0.00%
0.00%
0.00%
0.00%
0.00%
+0.51%
0.00%Popular Instruments
52003.400
+31.700 (+0.06%)
29859.700
+65.500 (+0.22%)
7415.900
+5.500 (+0.07%)
15808.000
+271.000 (+1.74%)
72318.000
+1361.000 (+1.92%)
6271.200
+43.000 (+0.69%)
69.724
-0.035 (-0.05%)
291.504
-1.576 (-0.54%)
200.580
+1.580 (+0.79%)
4028.180
+29.440 (+0.74%)
FAQs
What is the current price of Jazz Pharmaceuticals PLC (JAZZ)?
The current price of Jazz Pharmaceuticals PLC (JAZZ) is 229.85.
What is the symbol of Jazz Pharmaceuticals PLC?
The ticker symbol of Jazz Pharmaceuticals PLC is JAZZ.
What is the 52-week high of Jazz Pharmaceuticals PLC?
The 52-week high of Jazz Pharmaceuticals PLC is 243.32.
What is the 52-week low of Jazz Pharmaceuticals PLC?
The 52-week low of Jazz Pharmaceuticals PLC is 105.00.
What is the market capitalization of Jazz Pharmaceuticals PLC?
The market capitalization of Jazz Pharmaceuticals PLC is 14.44B.
Is Jazz Pharmaceuticals PLC (JAZZ) currently rated as Buy, Hold, or Sell?
According to analysts, Jazz Pharmaceuticals PLC (JAZZ) has an overall rating of Buy, with a price target of 258.27.
What is the Earnings Per Share (EPS TTM) of Jazz Pharmaceuticals PLC (JAZZ)?
The Earnings Per Share (EPS TTM) of Jazz Pharmaceuticals PLC (JAZZ) is -5.84.
